Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
Public ClinicalTrials.gov record NCT00496197. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to further evaluate the safety and effectiveness of intravenous anidulafungin (Eraxis™) in patients with a diagnosis of candidemia or invasive candidiasis, which is a fungus infection of the blood or tissue. Currently the drug is approved for treatment using a daily dose of IV medication until 14 days after the fungus disappears from the blood. This study will evaluate the effectiveness of intravenous anidulafungin when it is administered for 5-28 days followed by oral antifungal medication. Study patients will be assessed for response to treatment throughout the study drug treatment period.
Study identification
- NCT ID
- NCT00496197
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 282 participants
Conditions and interventions
Conditions
Interventions
- Eraxis (anidulafungin) Drug
- Diflucan (fluconazole) Drug
- Vfend (voriconazole) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2007 (Type not available)
- Primary completion
- Jun 2010 (Actual)
- Completion
- Jun 2010 (Actual)
- Last update posted
- Oct 3, 2011
2007 – 2010
United States locations
- U.S. sites
- 39
- U.S. states
- 19
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35233 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35294 | — |
| Pfizer Investigational Site | Little Rock | Arkansas | 72205 | — |
| Pfizer Investigational Site | Los Angeles | California | 90033 | — |
| Pfizer Investigational Site | San Francisco | California | 94115 | — |
| Pfizer Investigational Site | San Francisco | California | 94143 | — |
| Pfizer Investigational Site | Newark | Delaware | 19713 | — |
| Pfizer Investigational Site | Newark | Delaware | 19718 | — |
| Pfizer Investigational Site | Wilmington | Delaware | 19801 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20010 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32209 | — |
| Pfizer Investigational Site | Miami | Florida | 33136 | — |
| Pfizer Investigational Site | Orlando | Florida | 32801 | — |
| Pfizer Investigational Site | Orlando | Florida | 32806 | — |
| Pfizer Investigational Site | Orlando | Florida | 32819 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30322 | — |
| Pfizer Investigational Site | Springfield | Illinois | 62701 | — |
| Pfizer Investigational Site | Springfield | Illinois | 62702 | — |
| Pfizer Investigational Site | Springfield | Illinois | 62703-9248 | — |
| Pfizer Investigational Site | Springfield | Illinois | 62703 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21205 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21287 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48201 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48202 | — |
| Pfizer Investigational Site | Royal Oak | Michigan | 48073 | — |
| Pfizer Investigational Site | Minneota | Minnesota | 55455 | — |
| Pfizer Investigational Site | Butte | Montana | 59701 | — |
| Pfizer Investigational Site | Camden | New Jersey | 08103 | — |
| Pfizer Investigational Site | Albany | New York | 12208 | — |
| Pfizer Investigational Site | Buffalo | New York | 14263 | — |
| Pfizer Investigational Site | Rochester | New York | 14642 | — |
| Pfizer Investigational Site | Greenville | North Carolina | 27834-6028 | — |
| Pfizer Investigational Site | Greenville | North Carolina | 27834 | — |
| Pfizer Investigational Site | Portland | Oregon | 97239 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19140 | — |
| Pfizer Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| Pfizer Investigational Site | West Reading | Pennsylvania | 19611 | — |
| Pfizer Investigational Site | Charleston | South Carolina | 29414 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00496197, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 3, 2011 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00496197 live on ClinicalTrials.gov.